TTP607 in Refractory Solid Malignancies
Phase 1
Withdrawn
- Conditions
- Advanced CancersLymphoma
- Interventions
- Drug: TTP607
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00939172
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00939159
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Phase 2
Completed
- Conditions
- Testicular Cancer
- Interventions
- Drug: GemcitabineDrug: DocetaxelDrug: MesnaDrug: MelphalanDrug: IfosfamideDrug: CarboplatinDrug: EtoposideProcedure: Stem Cell Transplant
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00936936
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00936117
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer
Phase 2
Completed
- Conditions
- Advanced Cancers
- Interventions
- Device: VapothermDevice: BIPAP
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00934128
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Paclitaxel in Prostate Cancer
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00933426
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Impact of Obesity and Obesity Treatments on Breast Cancer
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00933309
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
Phase 2
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: Standard TherapyProcedure: Local Therapy
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00929214
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy
Not Applicable
Withdrawn
- Conditions
- Head and Neck CancerOropharyngeal CancerGastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00928161
Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy
Terminated
- Conditions
- Breast Cancer
- Interventions
- Procedure: Breast MRIProcedure: Mammogram
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00925405
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath